Differentially expressed genes between high-risk human papillomavirus types in human cervical cancer cells

被引:20
|
作者
Vazquez-Ortiz, G.
Garcia, J. A.
Ciudad, C. J.
Noe, V.
Penuelas, S.
Lopez-Romero, R.
Mendoza-Lorenzo, P.
Pina-Sanchez, P.
Salcedo, M.
机构
[1] Natl Med Ctr SXXI IMSS, Oncol Hosp, Unidad Invest Med Enfermedades Oncol, Oncol Res Unit,Lab Oncogenom, Mexico City 07780, DF, Mexico
[2] Keck Grad Inst Appl Life Sci, Claremont, CA USA
[3] Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Barcelona, Spain
关键词
cervical cancer; differential expression; HPV;
D O I
10.1111/j.1525-1438.2007.00831.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cervical carcinoma (CC) is one of the most common cancers among women worldwide and the first cause of death among the Mexican female population. Human papillomavirus (HPV) infection is the most important etiologic factor for CC. Of the oncogenic types, HPV16 and HPV18 are found in 60-70% of invasive CCs worldwide. HPV18 appears to be associated with a more aggressive form of cervical neoplasia than HPV16 infection. At present, there are no studies on differentially expressed cellular genes between transformed cells harboring HPV16 and HPV18 sequences. Based on previous complementaryDNA microarray data from our group, 13 genes were found to be differentially overexpressed between HPV16- and HPV18-transformed cells. These genes were as follows: E6BP, UBE4A, C20orf14, ATF7, ABCC8, SLC6A12, WASF3, SUV39H1, SPAG8, CCNC, E2FFE, BIRC5, and DEDD. Differential expression of six selected genes was confirmed by real-time reverse transcription-polymerase chain reaction (RT-PCR). All real-time RT-PCRs confirmed differential expression between HPV18 and HPV- samples. The present work identifies genes from signaling pathways triggered by HPV transformation that could be differentially deregulated between HPV16(+) and HPV18(+) samples.
引用
收藏
页码:484 / 491
页数:8
相关论文
共 50 条
  • [41] Understanding the high-risk human papillomavirus prevalence and associated factors in the European country with a high incidence of cervical cancer
    Berza, Natalija
    Zodzika, Jana
    Kivite-Urtane, Anda
    Baltzer, Nicholas
    Curkste, Alise
    Pole, Ilva
    Nygard, Mari
    Parna, Kersti
    Stankunas, Mindaugas
    Tisler, Anna
    Uuskula, Anneli
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2024, 34 (04) : 826 - 832
  • [42] Identification of High-risk Human Papillomavirus (hrHPV)-associated Genes in Early Stage Cervical Squamous Cell Carcinomas
    Hu, Y.
    Liu, Y.
    Liu, C-B
    Ling, Z-Q
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (03) : 712 - 728
  • [43] Cervical nitric oxide release and persistence of high-risk human papillomavirus in women
    Rahkola, Paivi
    Vaisanen-Tommiska, Mervi
    Tuomikoski, Pauliina
    Ylikorkala, Olavi
    Mikkola, Tomi S.
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (12) : 2933 - 2937
  • [44] Testing for high-risk human papillomavirus types will become a standard of clinical care
    Ledger, WJ
    Jeremias, J
    Witkin, SS
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (04) : 860 - 865
  • [45] Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance
    Huh, Warner K.
    Ault, Kevin A.
    Chelmow, David
    Davey, Diane D.
    Goulart, Robert A.
    Garcia, Francisco A.
    Kinney, Walter K.
    Massad, L. Stewart
    Mayeaux, Edward J.
    Saslow, Debbie
    Schiffman, Mark
    Wentzensen, Nicolas
    Lawson, Herschel W.
    Einstein, Mark H.
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2015, 19 (02) : 91 - 96
  • [46] Value of high-risk human papillomavirus detection combined with colposcopy in the diagnosis of cervical cancer and precancerous lesions
    Wang, Ping
    Gao, Dongxia
    Yu, Xiaoni
    Zhu, Gaoxiang
    ONCOLOGY LETTERS, 2024, 27 (04)
  • [47] Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Quebec, Canada
    Vijayaraghavan, Arthi
    Efrusy, Molly B.
    Mayrand, Marie-Helene
    Santas, Christopher C.
    Goggin, Patricia
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2010, 101 (03): : 220 - 225
  • [48] Telomerase reverse transcriptase gene polymorphisms and cervical cancer susceptibility in high-risk human papillomavirus-infected women
    Sun, Shuang
    Wang, Yuhong
    Liu, Ying
    Leng, Zongxiang
    Jiang, Yujuan
    Liang, Yu
    Jiang, Zhe
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (01) : 95 - 102
  • [49] Survivin as a marker of cervical intralepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer
    Branca, M
    Giorgi, C
    Santini, D
    Di Bonito, L
    Ciotti, M
    Costa, S
    Benedetto, A
    Casolati, EA
    Favalli, C
    Paba, P
    Di Bonito, P
    Mariani, L
    Syrjänen, S
    Bonifacio, D
    Accardi, L
    Zanconati, F
    Syrjänen, K
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (01) : 113 - 121
  • [50] Association between human papillomavirus vaccine status and other cervical cancer risk factors
    Bowyer, Harriet L.
    Dodd, Rachael H.
    Marlow, Laura A. V.
    Waller, Jo
    VACCINE, 2014, 32 (34) : 4310 - 4316